

Market Scope®

2025 Glaucoma Pharmaceuticals Market Report

Global Analysis for 2024 to 2030

\$3.8B

2025 MARKET
FORECAST

250

COMPREHENSIVE
PAGES

25

COMPETITOR
PROFILES

8

GEOGRAPHIC AND
ECONOMIC BREAKOUTS

What's New

AUTHOR
Peter Downs

PUBLISHED
April 2025

The “2025 Glaucoma Pharmaceuticals Market Report” features new regional sales forecasts that consider appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma.

The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan, prescription stratification by first-line and adjunctive use in the United States and Western European countries, and survey data on Western European ophthalmologists’ plans for sustained drug delivery.

Market Scope


2025 Glaucoma Pharmaceuticals Market Report

The “2025 Glaucoma Pharmaceuticals Market Report” delivers a deep analysis of global and regional markets, pinpointing key trends and critical drivers of future growth. It presents detailed forecasts through 2030 for major drug classes, including branded and generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combinations, NO-donating compounds, and Rho-kinase inhibitors.


The report highlights more than 30 pipeline drugs currently in development, offering insight into the future treatment landscape. It also features in-depth profiles of 25 pharmaceutical companies, examining their product portfolios, competitive positioning, strategic direction, and long-term outlook. Coverage includes:

- Types of glaucoma and risk factors.
- Diagnosis and treatment of the disease.
- A global view of glaucoma care providers, including ophthalmologists and optometrists.
- Current estimates and five-year forecasts for disease prevalence worldwide.
- Glaucoma medications in the marketplace and their mechanisms of action.
- Discussion of generic versus branded drugs and their market impact.
- The development pipeline for glaucoma pharmaceuticals.
- Profiles of companies making and marketing glaucoma medications.

**Glaucoma Pharmaceuticals Sales Revenue
by Region**



**Glaucoma Pharmaceuticals Revenue
by Market Competitor**



This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

How to Order

Order your "2025 Glaucoma Pharmaceuticals Market Report" now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2025 Glaucoma Pharmaceuticals
Market Report

\$12,750

*(Price includes a printable PDF and
supplemental Excel file with all the
tables and figures in the report)*



SINGLE-USER LICENSE

2025 Glaucoma Pharmaceuticals
Market Report

\$8,500



Printed Copy

\$250



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter

\$1,650



Monthly Paper Copies

\$100

314.835.0600 | info@market-scope.com

Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

